Predicting Hematologic Toxicity in Patients Undergoing Radioimmunotherapy with ⁹⁰Y-Ibritumomab Tiuxetan or ¹³¹I-Tositumomab

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.